Parametric Time-to-Event Model for Acute Exacerbations in Idiopathic Pulmonary Fibrosis

被引:4
作者
Tang, Fei [1 ,2 ]
Weber, Benjamin [1 ]
Stowasser, Susanne [3 ]
Korell, Julia [1 ]
机构
[1] Boehringer Ingelheim Pharmaceut Inc, Translat Med & Clin Pharmacol, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
[2] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY USA
[3] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
来源
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY | 2020年 / 9卷 / 02期
关键词
RISK-FACTORS; PIRFENIDONE; NINTEDANIB; SURVIVAL; CAPACITY; OUTCOMES; TRIAL;
D O I
10.1002/psp4.12485
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We describe a parametric time-to-event model for idiopathic pulmonary fibrosis (IPF) exacerbations and identify predictors of exacerbation risk using data obtained for the tyrosine-kinase inhibitor nintedanib in two phase III studies (INPULSIS-1/2). Parametric survival analysis was performed on time to first exacerbation (censoring on day 372), with univariate analysis to select statistically significant covariates (P = 0.05). Multivariate covariate models were developed using stepwise covariate modeling with forward inclusion (P = 0.05) and backward elimination (P = 0.01). Sixty-three first exacerbation events were reported across 1,061 subjects in the INPULSIS studies. Baseline and decline of forced vital capacity (FVC)/percent-predicted FVC (%pFVC), supplemental oxygen use, baseline CO diffusing capacity and age were statistically significant in the univariate analysis. The final covariate model included decline in FVC to week 52, baseline %pFVC, supplemental oxygen use, and age. The developed model may be used to identify patients at high risk of IPF exacerbations and accelerate development of novel treatments.
引用
收藏
页码:87 / 95
页数:9
相关论文
共 26 条
  • [1] Outcomes in idiopathic pulmonary fibrosis: A meta-analysis from placebo controlled trials
    Atkins, C. P.
    Loke, Y. K.
    Wilson, A. M.
    [J]. RESPIRATORY MEDICINE, 2014, 108 (02) : 376 - 387
  • [2] Approach to acute exacerbation of idiopathic pulmonary fibrosis
    Bhatti, Hammad
    Girdhar, Ankur
    Usman, Faisal
    Cury, James
    Bajwa, Abubakr
    [J]. ANNALS OF THORACIC MEDICINE, 2013, 8 (02) : 71 - 77
  • [3] Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis
    Brownell, Robert
    Kaminski, Naftali
    Woodruff, Prescott G.
    Bradford, Williamson Z.
    Richeldi, Luca
    Martinez, Fernando J.
    Collard, Harold R.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193 (11) : 1213 - 1218
  • [4] Acute exacerbations of idiopathic pulmonary fibrosis
    Collard, Harold R.
    Moore, Bethany B.
    Flaherty, Kevin R.
    Brown, Kevin K.
    Kaner, Robert J.
    King, Talmadge E., Jr.
    Lasky, Joseph A.
    Loyd, James E.
    Noth, Imre
    Olman, Mitchell A.
    Raghu, Ganesh
    Roman, Jesse
    Ryu, Jay H.
    Zisman, David A.
    Hunninghake, Gary W.
    Colby, Thomas V.
    Egan, Jim J.
    Hansell, David M.
    Johkoh, Takeshi
    Kaminski, Naftali
    Kim, Dong Soon
    Kondoh, Yasuhiro
    Lynch, David A.
    Mueller-Quernheim, Joachim
    Myers, Jeffrey L.
    Nicholson, Andrew G.
    Selman, Moises
    Toews, Galen B.
    Wells, Athol U.
    Martinez, Fernando J.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2007, 176 (07) : 636 - 643
  • [5] Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis
    Collard, Harold R.
    Richeldi, Luca
    Kim, Dong Soon
    Taniguchi, Hiroyuki
    Tschoepe, Inga
    Luisetti, Maurizio
    Roman, Jesse
    Tino, Gregory
    Schlenker-Herceg, Rozsa
    Hallmann, Christoph
    du Bois, Roland M.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2017, 49 (05)
  • [6] Acute Exacerbation of Idiopathic Pulmonary Fibrosis An International Working Group Report
    Collard, Harold R.
    Ryerson, Christopher J.
    Corte, Tamera J.
    Jenkins, Gisli
    Kondoh, Yasuhiro
    Lederer, David J.
    Lee, Joyce S.
    Maher, Toby M.
    Wells, Athol U.
    Antoniou, Katerina M.
    Behr, Juergen
    Brown, Kevin K.
    Cottin, Vincent
    Flaherty, Kevin R.
    Fukuoka, Junya
    Hansell, David M.
    Johkoh, Takeshi
    Kaminski, Naftali
    Kim, Dong Soon
    Kolb, Martin
    Lynch, David A.
    Myers, Jeffrey L.
    Raghu, Ganesh
    Richeldi, Luca
    Taniguchi, Hiroyuki
    Martinez, Fernando J.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 194 (03) : 265 - 275
  • [7] Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis
    Judge, Eoin P.
    Fabre, Aurelie
    Adamali, Huzaifa I.
    Egan, Jim J.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2012, 40 (01) : 93 - 100
  • [8] A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
    King, Talmadge E., Jr.
    Bradford, Williamson Z.
    Castro-Bernardini, Socorro
    Fagan, Elizabeth A.
    Glaspole, Ian
    Glassberg, Marilyn K.
    Gorina, Eduard
    Hopkins, Peter M.
    Kardatzke, David
    Lancaster, Lisa
    Lederer, David J.
    Nathan, Steven D.
    Pereira, Carlos A.
    Sahn, Steven A.
    Sussman, Robert
    Swigris, Jeffrey J.
    Noble, Paul W.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (22) : 2083 - 2092
  • [9] Kondoh Y, 2010, SARCOIDOSIS VASC DIF, V27, P103
  • [10] Risk factors for acute exacerbation of idiopathic pulmonary fibrosis - Extended analysis of pirfenidone trial in Japan
    Kondoh, Yasuhiro
    Taniguchi, Hiroyuki
    Ebina, Masahito
    Azuma, Arata
    Ogura, Takashi
    Taguchi, Yoshio
    Suga, Moritaka
    Takahashi, Hiroki
    Nakata, Koichiro
    Sugiyama, Yukihiko
    Kudoh, Shoji
    Nukiwa, Toshihiro
    [J]. RESPIRATORY INVESTIGATION, 2015, 53 (06) : 271 - 278